佛慈制药
(002644)
| 流通市值：44.94亿 | | | 总市值：44.94亿 |
| 流通股本：5.11亿 | | | 总股本：5.11亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 624,055,200.7 | 429,365,466.8 | 216,124,672.92 | 980,225,387.73 |
| 营业收入 | 624,055,200.7 | 429,365,466.8 | 216,124,672.92 | 980,225,387.73 |
| 二、营业总成本 | 564,312,051.85 | 380,743,426.65 | 189,743,028.4 | 903,743,257.88 |
| 营业成本 | 418,622,128.29 | 283,945,418.43 | 142,041,673.69 | 680,513,278.37 |
| 税金及附加 | 10,851,900.11 | 7,297,901.64 | 3,945,047.38 | 14,095,061.43 |
| 销售费用 | 72,223,250.25 | 46,903,224.22 | 20,231,809.02 | 116,044,604.78 |
| 管理费用 | 47,148,064.22 | 31,729,859.9 | 16,347,923.44 | 68,957,995.3 |
| 研发费用 | 18,073,933.17 | 13,281,225.46 | 7,741,713.66 | 29,284,084.57 |
| 财务费用 | -2,607,224.19 | -2,414,203 | -565,138.79 | -5,151,766.57 |
| 其中:利息费用 | 1,681,584.62 | 378,448.66 | - | 831,438.63 |
| 其中:利息收入 | 4,286,751.49 | 2,831,725.28 | - | 5,743,444.14 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -5,614,526.6 | -3,921,948.13 | -1,015,474.66 | -7,233,165.17 |
| 资产处置收益 | 1,415.92 | 1,415.92 | 1,415.92 | 40,438.07 |
| 资产减值损失(新) | - | - | - | -151,744.5 |
| 信用减值损失(新) | -28,861,144.13 | -21,479,697.36 | -8,024,525.12 | -33,666,912.41 |
| 其他收益 | 18,314,145.48 | 11,384,545.76 | 5,568,578.12 | 34,974,982.54 |
| 四、营业利润 | 43,583,039.52 | 34,606,356.34 | 22,911,638.78 | 70,445,728.38 |
| 加:营业外收入 | 429,246.1 | 1,322,171.77 | 894,830.1 | 435,595.54 |
| 减:营业外支出 | 1,736,405.4 | 1,289,781.43 | 73,627.47 | 1,741,820.55 |
| 五、利润总额 | 42,275,880.22 | 34,638,746.68 | 23,732,841.41 | 69,139,503.37 |
| 减:所得税费用 | 5,131,118.49 | 4,692,312.26 | 3,608,602.78 | 7,473,892.6 |
| 六、净利润 | 37,144,761.73 | 29,946,434.42 | 20,124,238.63 | 61,665,610.77 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 37,144,761.73 | 29,946,434.42 | 20,124,238.63 | 61,665,610.77 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 38,082,371.36 | 30,104,611.31 | 19,381,644.03 | 60,069,813.05 |
| 少数股东损益 | -937,609.63 | -158,176.89 | 742,594.6 | 1,595,797.72 |
| 扣除非经常损益后的净利润 | 23,809,045.68 | 20,850,937.98 | 14,350,387.51 | 32,406,746.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.06 | 0.04 | 0.12 |
| (二)稀释每股收益 | 0.07 | 0.06 | 0.04 | 0.12 |
| 八、其他综合收益 | 43,576.26 | 43,576.26 | - | 130,949.54 |
| 归属于母公司股东的其他综合收益 | 22,469.01 | 22,469.01 | - | 68,427.66 |
| 九、综合收益总额 | 37,188,337.99 | 29,990,010.68 | 20,124,238.63 | 61,796,560.31 |
| 归属于母公司股东的综合收益总额 | 38,104,840.37 | 30,127,080.32 | 19,381,644.03 | 60,138,240.71 |
| 归属于少数股东的综合收益总额 | -916,502.38 | -137,069.64 | 742,594.6 | 1,658,319.6 |
| 公告日期 | 2025-10-29 | 2025-08-27 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |